Focusing on cardio-hepatic syndrome in heart failure and cardiovascular interventions: Is it time to update the prognostic risk scores?

dc.authorid0000-0002-4281-0867
dc.contributor.authorKaraca, Oğuz
dc.date.accessioned2023-08-07T10:12:21Z
dc.date.available2023-08-07T10:12:21Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.description.abstractHeart failure (HF) is a multifactorial, heterogeneous disease characterized by congestion and/or reduced cardiac output, leading to unmet metabolic demands of vital organs. Regardless of the etiology or phenotypic features (ischemic vs. non-ischemic, reduced or preserved ejection fraction, severe valvular stenosis or regurgitation), the “inevitable consequence” of the HF syndrome is the progressive end-organ dysfunction. Failure of one or more organ systems (heart itself, lungs, kidneys, liver, intestine, brain, skeletal muscle) has been the main determinant of survival in HF.1,2 Integration of new pharmacologic agents (saqubitril/valsartan, sodium-glucose cotransporter-2 (SGLT-2) inhibitors) into guideline-directed medical therapy and advancements in interventional and surgical procedures (complex coronary interventions, transcatheter aortic valve implantation (TAVI), Mitra-clip, left ventricular assist devices) have led to a significant improvement in HF mortality in selected patients.3-7 However, HF still remains a global health problem associated with reduced survival, frequent hospitalizations, and impaired quality of life.
dc.identifier.citationKaraca, O. (2023). Focusing on cardio-hepatic syndrome in heart failure and cardiovascular interventions: Is it time to update the prognostic risk scores? Archives of the Turkish Society of Cardiology, 51(5), 304-305. https://dx.doi.org/10.5543/tkda.2023.25425
dc.identifier.doi10.5543/tkda.2023.25425
dc.identifier.endpage305
dc.identifier.issnhttps://dx.doi.org/10.5543/tkda.2023.25425
dc.identifier.issn1016-5169
dc.identifier.issn1308-4488
dc.identifier.issue5
dc.identifier.pmid37450457
dc.identifier.scopus2-s2.0-85164756047
dc.identifier.scopusqualityQ4
dc.identifier.startpage304
dc.identifier.trdizinid1189205
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11278
dc.identifier.volume51
dc.identifier.wos001046684700002en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthorKaraca, Oğuz
dc.language.isoen
dc.publisherTurkish Society of Cardiology
dc.relation.ispartofArchives of the Turkish Society of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectPrognostic Risk Scores
dc.subjectUpdate
dc.subjectCardiovascular Interventions
dc.subjectHeart Failure
dc.titleFocusing on cardio-hepatic syndrome in heart failure and cardiovascular interventions: Is it time to update the prognostic risk scores?
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Karaca-Oguz-2023.pdf
Boyut:
378.44 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: